Sputum Culture Conversion With Moxifloxacin-Containing Regimens in the Treatment of Patients With Newly Diagnosed Sputum-Positive Pulmonary Tuberculosis in South India
Author(s) -
Banurekha Velayutham,
I. S. Allaudeen,
Gomathi Narayan Sivaramakrishnan,
Perumal Vanamail,
Diir,
Chinnaiyan Ponnuraja,
Paulkumaran Paramasivam,
Dhanaraj Baskaran,
Ramesh Santhanakrishnan,
G. P. Navaneethapandian,
Makeshkumar Marimuthu,
Vanaja Kumar,
Cinthana Kandasamy,
K. Dharuman,
T. Elangovan,
Meenakshi Narasimhan,
Sridhar Rathinam,
V. Gangadharan,
Prabhakaran Rathinam,
Chandrasekar Chockalingam,
L. Jayabal,
Soumya Swaminathan,
Jawahar Mohideen Shaheed
Publication year - 2014
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciu550
Subject(s) - moxifloxacin , medicine , sputum , sputum culture , pyrazinamide , ethambutol , regimen , culture conversion , rifampicin , tuberculosis , surgery , isoniazid , antibiotics , pathology , microbiology and biotechnology , biology
Rapid sputum culture conversion at 2 months indicates the sterilizing capacity and potential of regimens to shorten duration of tuberculosis treatment. We compared results of sputum culture conversion by moxifloxacin and control regimens and identified factors affecting sputum culture positivity after 2 months of treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom